2. DESCRIPTION:
Ikgdar 500mg is a anticancer medicine which prevents the
growth and spread of cancer cells in the body.
Ikgdar 500mg injection also indicated for the treatment of
Non- Hodgkins lymphoma or chronic lymphocytic and
with combination with another anticancer drugs like
methotrexate is used for rheumatoid arthritis symptoms in
adult treatment.
Ikgdar 500mg with steroid regimen combination is given
for the treatment of some rare disorders which cause blood
vessels and other tissues inflammation in the body.
3. INDICATION
Ikgdar 500mg injection and hyaluronidase human
injection are given alone or combination with another
drugs to treat certain types of non-Hodgkin's
lymphoma and chronic lymphocytic leukemia (cancer
start in WBC).
Ikgdar 500mg injection is also used with methotrexate
(Otrexup, Rasuvo, Xatmep, others) for the treatment
rheumatoid arthritis symptoms in adults that have
been already treated with a some type of regimen
known as tumor necrosis factor (TNF) inhibitor.
5. PHARMACODYNAMIC:
new type of "targeted" cancer treatment and an
integral part of the body's immune system. Naturally
the body build antibodies in along with to an antigen
which has entered the body and attach to the antigen
for destruction by the immune system. An essential
cells only aimed by monoclonal antibiotics, they may
leads to less toxicity to healthy cell and it is usually
treatment recommended only for cancers in which
antigens (and the respective antibodies) have been
already identified.
7. PHARMACOKINETICS:
ABSORPTION:
Not available
DISTRIBUTION:
volume of distribution is 3.1 L
METABOLISM:
Ikgdar 500mg injection metabolized by human
antimurine antibody production.
EXCRETION
not available The half life of NHL is 22 days and for RA
is 18.0 days, GPA and microscopic polyangitis is 23 days
8. DOSAGE MANAGEMENT:
Ikgdar 500mg is recommended to administer only through
intravenous infusion not by IV push or bolus.
ADMINISTRATION:
Take an Ikgdar 500mg injection amount and diluted to
final concentration of 1 mg/ml upto 4 mg/ml as infusion
(containing either 0.9% Nacl or 5% dextrose in water).
Invert gently the bag and mix the solution. Dispose unused
drug left in vial.
OVERDOSAGE:
If the patients had high dose of Ikgdar 500mg then seek
immediately to the emergency department or poison
control help line. Please consult the doctor for further
clarification.
9. DRUG INTERACTION:
Ikgdar 500mg injection drug interaction has limited
data is available at present. Combination with
fludarabine or cyclophosphamide has no effects in
pharmacokinetics in CLL patients. Combination with
methotrexate had no effects in pharmacokinetics.
11. PREGNANCY:
CategoryC : animal studies reproduction shown an
adverse effect on the fetus. The drug has no sufficient
and well controlled studies in humans, using in
pregnant women benefits by warrant use of the drug.
12. LACTATION:
Ikgdar 500mg excreted into human milk is unknown.
Due to the drug belongs to large protein molecule, no
information is available. Women should not breast
feed during Ikgdar 500mg treatment and 12 months
following last dose.
13. STORAGE :
Store at 2°C – 3°C
Use the drug before expiry date
Protected from direct sunlight
Do not freeze or shake.
Keep away from the childerns
Discard the unused drug by asking the advice from
doctor or pharmacist.
14. MISSED DOSE:
If a dose missed to take at the time then have it
suddenly before next dose timing, if time reach for
next dose, then skip missed dose and continue and
continue the regular schedule. Do not have 2 dose at a
same time.
15. CONTACT US:
EMAIL ID : millionhealthpharmaceuticals@gmail.com
PHONE NO : +91-9940472902
WEBSITE URL : https://millionpharma.com/ikgdar-
500mg.php